The reduction will go a long way in boosting economic growth and will act as a stimulant for Indian firms to invest more on capex Business Standard, 5 days ago
US will be a strong driver for the company in the next few years: Glenn Saldanha, Glenmark Pharmaceuticals Ltd
unching, getting six or seven approvals over the last three or four months, and most of them were launched in the quarter." In an interview with ET Now, Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd, talks about his views on ...Economic Times, 2 months ago
MUMBAI Indian drugmaker Glenmark Pharmaceuticals ( GLEN.NS ) is counting on strong growth in the United States, where it will launch a dozen new medicines, to offset weakness in emerging markets this year, its chief executive said. One of India's ...Reuters India, 1 week ago Glenmark Bets on US Sales to Offset Emerging Market Weakness NDTV, 1 week ago
"The US business remains a critical growth driver and our efforts will be to maximise our presence and earnings from this market," Glenmark Pharma Chairman MD Glenn Saldanha told shareholders at the company's AGM here.Money Control, 1 week ago
Phase I clinical studies has been completed by Glenmark Pharmaceuticals for their novel monoclonal antibody 'GBR 830' for treating autoimmune diseases. While phase I trials took place in the Netherlands, the company said it will initiate the ...MedIndia, 1 month ago Glenmark's Novel Monoclonal Antibody GBR 830 To Enter Phase 2 Clinical Studies In Atopic Dermatitis And Celiac Disease In US And Europe TheStreet.com, 1 month ago
Glenmark Pharmaceuticals on Thursday posted 3.29 per cent rise in consolidated net profit at Rs 190.93 crore for the first quarter ended June 30, driven by sales in domestic as well as overseas markets. The Mumbai-based company had posted a net profit of Rs ...The Financial Chronicle, 2 months ago
on your WebpageAdd Widget >Get your members hooked!